Mogrify Alternatives & Competitors
12 companies similar to Mogrify — Transforming the lives of patients with degenerative diseases through a novel cl...
Companies similar to Mogrify
Aspen Neuroscience, Inc.
Developing autologous iPSC-derived cell replacement therapies for Parkinson’s disease and...
La Jolla, United States
Octant
Developing synthetic technology and applying next-generation DNA sequencing, gene synthesi...
Emeryville, United States
Replay
Reprogramming biology by writing and delivering big DNA
San Diego, United States
Cellarity
Rewriting the rules of drug creation
Somerville, United States
Rival Readout
Competing with Mogrify? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Life Biosciences
Targeting the biology of aging
Boston, United States
nextgem-inc
developing novel curative treatment method with limited side effects, focusing on the poss...
Japan
Tenaya Therapeutics
Scaling new heights in the fight against heart disease
South San Francisco, Unit...
bit.bio
The Cell Coding Company
Cambridge, United Kingdom
CytoNiche
Pioneering 3D micro-organization engineering for advanced stem cell solutions, inspired by...
BlueRock Therapeutics
Striving to transform the treatment of disease by harnessing the power of cell therapy
Cambridge, United States
Macomics
Macrophage Biology Revealed:Developing breakthrough approaches to macrophage activity to c...
Edinburgh, United Kingdom
Rejuvenate Bio
Targeting the core drivers of chronic age-related diseases to reverse pre-existing conditi...
About Mogrify
Mogrify is leveraging its proprietary platform technologies to revolutionize treatment methods for degenerative diseases through a new class of in vivo reprogramming therapies. Established in 2019 and headquartered in the United Kingdom, the company has positioned itself to penetrate the burgeoning regenerative medicin...
Development of in vivo reprogramming therapies, Direct cellular reprogramming, Cell identity platform development, Therapeutic co-development partnerships
Biopharmaceutical companies, Healthcare institutions, Regenerative medicine innovators, Research organizations focusing on degenerative diseases
Regenerative Medicine, Cell Therapy, Stem Cell Research, Drug Discovery, Gene Therapy, Transcriptomics, Bioinformatics, Machine Learning, Direct Cellular Conversion, In Vivo Reprogramming, Ophthalmology, Otology, Metabolic Diseases, Research And Development
Platform, B2B, PaaS
Licensing, Product Sales, Project Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Mogrify: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Mogrify on 25 Mar 2025. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
